Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Does switching anti-TNFα biologic agents represent an effective option in childhood chronic uveitis: the evidence from a systematic review and meta-analysis approach.

Simonini G, Katie D, Cimaz R, Macfarlane GJ, Jones GT.

Semin Arthritis Rheum. 2014 Aug;44(1):39-46. doi: 10.1016/j.semarthrit.2014.03.001. Epub 2014 Mar 6. Review.

PMID:
24709278
2.

Current evidence of anti-tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs.

Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT.

Arthritis Care Res (Hoboken). 2014 Jul;66(7):1073-84. doi: 10.1002/acr.22214. Review.

3.

Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review.

Simonini G, Cimaz R, Jones GT, Macfarlane GJ.

Semin Arthritis Rheum. 2015 Oct;45(2):238-50. doi: 10.1016/j.semarthrit.2015.05.006. Epub 2015 May 21. Review.

PMID:
26164255
4.

Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach.

Simonini G, Paudyal P, Jones GT, Cimaz R, Macfarlane GJ.

Rheumatology (Oxford). 2013 May;52(5):825-31. doi: 10.1093/rheumatology/kes186. Epub 2012 Aug 9. Review.

PMID:
22879466
5.

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis.

Simonini G, Taddio A, Cattalini M, Caputo R, de Libero C, Parentin F, Pagnini I, Lepore L, Cimaz R.

Pediatr Rheumatol Online J. 2013 Apr 15;11:16. doi: 10.1186/1546-0096-11-16. eCollection 2013.

6.

Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry.

Zannin ME, Birolo C, Gerloni VM, Miserocchi E, Pontikaki I, Paroli MP, Bracaglia C, Shardlow A, Parentin F, Cimaz R, Simonini G, Falcini F, Corona F, Viola S, De Marco R, Breda L, La Torre F, Vittadello F, Martini G, Zulian F.

J Rheumatol. 2013 Jan;40(1):74-9. doi: 10.3899/jrheum.120583. Epub 2012 Nov 1. Erratum in: J Rheumatol. 2013 Jan;40(1):106.

PMID:
23118110
7.

Anti-TNFα Treatment for HLA-B27-Positive Ankylosing Spondylitis-Related Uveitis.

Kim M, Won JY, Choi SY, Ju JH, Park YH.

Am J Ophthalmol. 2016 Oct;170:32-40. doi: 10.1016/j.ajo.2016.07.016. Epub 2016 Jul 25.

PMID:
27470062
8.

Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.

Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.

J Rheumatol. 2007 May;34(5):1146-50. Epub 2007 Mar 1.

PMID:
17343318
9.

Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study.

Spadaro A, Punzi L, Marchesoni A, Lubrano E, Mathieu A, Cantini F, Olivieri I, Salvarani C, Scarpa R, Scrivo R, Ramonda R, Porru G, D'Angelo S, Catanoso M, Atteno M, Valesini G.

Rheumatology (Oxford). 2010 Jun;49(6):1107-11. doi: 10.1093/rheumatology/keq008. Epub 2010 Mar 11.

PMID:
20223813
10.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

11.

Uveitis Reactivation in Children Treated With Tumor Necrosis Factor Alpha Inhibitors.

Lerman MA, Lewen MD, Kempen JH, Mills MD.

Am J Ophthalmol. 2015 Jul;160(1):193-200.e1. doi: 10.1016/j.ajo.2015.04.016. Epub 2015 Apr 17.

12.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

13.

[Anti-TNFalpha treatment of juvenile uveitis].

Fledelius HC, Nielsen SM, Nissen KR, Pedersen FK, Zak MS.

Ugeskr Laeger. 2007 Apr 2;169(14):1309-12. Danish.

PMID:
17437693
14.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
15.

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.

Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, Cordero-Coma M, García-Aparicio ÁM, Valls Pascual E, Martínez-Costa L, Hernández MV, Hernandez Garfella M, González-Vela MC, Pina T, Palmou-Fontana N, Loricera J, Hernández JL, González-Gay MA.

Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S34-S40. Epub 2016 Apr 7.

PMID:
27054359
16.

Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation.

Galor A, Perez VL, Hammel JP, Lowder CY.

Ophthalmology. 2006 Dec;113(12):2317-23. Epub 2006 Sep 25.

PMID:
16996615
17.

Infliximab Versus Adalimumab in the Treatment of Refractory Inflammatory Uveitis: A Multicenter Study From the French Uveitis Network.

Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, Bienvenu B, Abad S, Rigolet A, Deroux A, Sene D, Perlat A, Marie I, Feurer E, Hachulla E, Fain O, Clavel G, Riviere S, Bouche PA, Gueudry J, Pugnet G, Le Hoang P, Resche Rigon M, Cacoub P, Bodaghi B, Saadoun D; French Uveitis Network.

Arthritis Rheumatol. 2016 Jun;68(6):1522-30. doi: 10.1002/art.39667.

18.

Switching biologic agents for uveitis.

Dhingra N, Morgan J, Dick AD.

Eye (Lond). 2009 Sep;23(9):1868-70. doi: 10.1038/eye.2009.203. Epub 2009 Jul 31.

PMID:
19648889
19.

Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K.

Ann Rheum Dis. 2007 Apr;66(4):548-50. Epub 2006 Oct 26.

20.

Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.

Saurenmann RK, Levin AV, Rose JB, Parker S, Rabinovitch T, Tyrrell PN, Feldman BM, Laxer RM, Schneider R, Silverman ED.

Rheumatology (Oxford). 2006 Aug;45(8):982-9. Epub 2006 Feb 3.

PMID:
16461435

Supplemental Content

Support Center